Literature DB >> 14511365

Impact of parturition on iron status in nonanaemic iron deficiency.

A Krafft1, R Huch, C Breymann.   

Abstract

BACKGROUND: Iron-deficient nonanaemic parturients risk underdiagnosis as a result of the reliance on postpartum ferritin and haemoglobin as markers of iron status. Ferritin is an acute-phase protein whose levels increase during the inflammatory response, as occurs after delivery. Our aims were to evaluate the impact of parturition on iron status, erythropoiesis and the inflammatory response, and identify the optimal parameters and timing for diagnosing iron deficiency in the presence of postpartum inflammation.
MATERIALS AND METHODS: Conventional parameters of iron status, erythropoiesis and the inflammatory response (serum ferritin, serum iron, transferrin saturation, C-reactive protein) were compared with more recent parameters [soluble transferrin receptors (sTfR), hypochromic red cells, reticulocyte indices] within 48 h either side of delivery in 64 iron-deficient nonanaemic women (defined by a prepartum serum ferritin < or =15 microg L(-1), and a pre- and postpartum haemoglobin of > or =11.0 g dL(-1) and > or =10.0 g dL(-1), respectively).
RESULTS: Mean sTfR decreased pre to postpartum from 7.3 to 5.8 microg mL(-1) (P<0.01), while mean serum ferritin increased from 9.7 to 16.9 microg L(-1) (P<0.01). Serum ferritin did not correlate with haemoglobin pre or postpartum (r=0.04, P=0.7; r=0.2, P=0.09), but a correlation persisted postpartum between hypochromic red blood cells and haemoglobin (r=-0.26; P<0.05). The percentage of hypochromic red cells remained virtually unchanged pre- and postpartum (4.0% vs. 3.8%; NS). Postpartum mean reticulocyte haemoglobin content (CHr) was 27.1 +/- 1.6 pg.
CONCLUSION: Iron status should be tested prepartum, in the absence of an inflammatory response, rather than in the early postpartum. A valuable additional parameter, where available, might be the hypochromic red cell percentage, which is virtually uninfluenced by the inflammatory response. Furthermore, hypochromic red cell percentage, CHr and sTfR can be helpful to differentiate between functional iron deficiency and depleted iron stores.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511365     DOI: 10.1046/j.1365-2362.2003.01244.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  6 in total

1.  Management of Iron Deficiency Anemia in Pregnancy in India.

Authors:  Rimpy Tandon; Arihant Jain; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2018-03-14       Impact factor: 0.900

2.  Patient blood management in obstetrics: prevention and treatment of postpartum haemorrhage. A NATA consensus statement.

Authors:  Manuel Muñoz; Jakob Stensballe; Anne-Sophie Ducloy-Bouthors; Marie-Pierre Bonnet; Edoardo De Robertis; Ino Fornet; François Goffinet; Stefan Hofer; Wolfgang Holzgreve; Susana Manrique; Jacky Nizard; François Christory; Charles-Marc Samama; Jean-François Hardy
Journal:  Blood Transfus       Date:  2019-02-06       Impact factor: 3.443

Review 3.  Ferrous versus ferric oral iron formulations for the treatment of iron deficiency: a clinical overview.

Authors:  Palacios Santiago
Journal:  ScientificWorldJournal       Date:  2012-05-02

4.  Long-term efficacy of postpartum intravenous iron therapy.

Authors:  Nadine Becuzzi; Roland Zimmermann; Alexander Krafft
Journal:  Biomed Res Int       Date:  2014-11-06       Impact factor: 3.411

5.  Effect of maternal iron deficiency anemia on the iron store of newborns in ethiopia.

Authors:  Betelihem Terefe; Asaye Birhanu; Paulos Nigussie; Aster Tsegaye
Journal:  Anemia       Date:  2015-02-04

6.  Patient blood management (PBM) in pregnancy and childbirth: literature review and expert opinion.

Authors:  Daniel Surbek; Yvan Vial; Thierry Girard; Christian Breymann; Gabriela Amstad Bencaiova; David Baud; René Hornung; Behrouz Mansouri Taleghani; Irene Hösli
Journal:  Arch Gynecol Obstet       Date:  2019-11-14       Impact factor: 2.344

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.